Medicsight PLC (AIM: MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software to assist in the early detection and diagnosis of disease, is pleased to announce its results for the first quarter ended 31 March 2009 which are in line with market expectations at this point in the calendar year.

Summary Financial Data

For the three months to 31 March 2009

• The Group's cash and equivalents balance at 31 March 2009 was £15,722,000 (31 December 2008: £18,387,000)
• The Group's total assets position at 31 March 2009 was £17,120,000 (31 December 2008: £19,958,000)
• net revenue from external customers was £43,000 (31 March 2008: £17,000)
• operating loss before interest and tax of £2,457,000 (31 March 2008: £2,030,000)

Allan Rowley, Chief Executive of Medicsight PLC commented "In the first quarter of 2009 we took the decision to streamline operating costs across the Group and protect our cash position. This meant deferring or cancelling some discretionary spend and reducing headcount. We have reviewed the product and clinical roadmap to ensure that the reduction in costs will not jeopardise our longer term business plans. This process has now largely been completed and we expect to see cost savings as the year progresses.

Regarding regulatory approvals we submitted our response to the Food & Drug Administration's (FDA) enquiries in March after working closely with our FDA advisers, and await further feedback on the 510(k) application made for ColonCAD. We also await a further update from the Ministry of Health, Labour and Welfare (MHLW) regulatory authorities in Japan.

In March 2009 we CE marked the latest version of the Medicsight ColonCAD 4.0 and formally launched this product at the European Congress of Radiology. This new release significantly reduces the number of false-positive CAD marks presented to a radiologist reviewing a patient data set. This should lead to further improvements in reader performance when assisted by the ColonCAD^™ software. The ColonCAD 4.0 upgrade will be integrated into our partner workstations and will be released into the European market during 2009."

For further information:
Medicsight plc
Allan Rowley, CEO
Tel: +44 (0)20 7605 7950
www.medicsight.com

Daniel Stewart & Co
Simon Leathers
Tel: +44 (0) 207 776 6550
www.danielstewart.co.uk

Media enquiries:
Abchurch Tel: +44 (0) 20 7398 7700
Heather Salmond/Stephanie Cuthbert/Simone Alves
Tel: +44 (0) 20 7398 7728
stephanie.cuthbert@abchurch-group.com
www.abchurch-group.com

Notes to editors
Medicsight PLC is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD^™ and LungCAD^™ software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

About Medicsight's CAD software
Medicsight's ColonCAD^™ and LungCAD^™ software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.